CD8A and cancer: Consequently, we conducted in vitro co-culture experiments involving primary cancer cells, TAMs, and CD8+ T cells, demonstrating that silencing BCAP31 in TAMs results in increased cytokine production and activation of CD8+ T cells, potentially leading to immunotherapy responsiveness.